Persistence of heroin use despite methadone treatment: Poor coping self-efficacy predicts continued heroin use

Drug and Alcohol Review

Volumn 28, Issue 6, 2009, Pages 608-615

  Senbanjo, Richard ^a,b   Wolff, Kim ^b   Marshall, E Jane ^b   Strang, John ^b  

^a KCA Community Drug Services   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cocaine use; Coping self efficacy; Heroin use; Low mood; Methadone treatment

Indexed keywords

METHADONE;

ADAPTIVE BEHAVIOR; ADULT; ARTICLE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; FORECASTING; HEROIN DEPENDENCE; HUMAN; MALE; PSYCHOLOGICAL ASPECT; SELF CONCEPT; TREATMENT OUTCOME; UNITED KINGDOM;

ADAPTATION, PSYCHOLOGICAL; ADULT; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; FORECASTING; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; SELF EFFICACY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76949100563     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2009.00064.x     Document Type: Article

References (38)

1. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and Buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11:13-28.
2. Bell J, Chan J, Kuk A. Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction 1995;90:823-30.
3. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000;57:395-404.
4. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin selfadministration in opioid-dependent volunteers. Addiction 2005;100:1496-509.
5. Teesson M, Ross J, Darke S, et al. One year outcomes for heroin dependence: findings from the AustralianTreatment Outcome Study (ATOS). Drug Alcohol Depend 2006; 83:174-80.
6. Dunn J, Zador D, Robjant K, Orr T, Hinton M. Notes from practice: methadone prescribing in north central London-doses, compliance goals and treatment setting. Drug Edu Prev Policy 2007;14:181-91.
7. Best D, Gossop M, Stewart D, Marsden J, Lehmann P, Strang J. Continued heroin use during methadone treatment: relationship between frequency of use and reasons reported for heroin use. Drug Alcohol Depend 1999;53: 191-5.
8. Best D, Ridge G. 'Using on top' and the problems it brings: additional drug use by methadone treatment patients. In: Tober G, Strang J, eds. Methadone matters: evolving community methadone treatment of opiate addiction. London: Martin Dunitz, 2003:141-54.
9. Masson CL, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 2004;99:718-26.
10. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 2004;74:123-34.
11. Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J 2007; 100:393-7.
12. Niaura R. Cognitive social learning and related perspectives on drug craving. Addiction 2000;95 (Suppl. 2):155-63.
13. Brewer DD, Catalano RF, Haggerty K, Gainey RR, Flemming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998;93:73-92.
14. Gossop M, Stewart D, Marsden J. Effectiveness of drug and alcohol counselling during methadone treatment: content, frequency, and duration of counselling and association with substance use outcomes. Addiction 2006;101:404-12.
15. Raistrick D. Linking psychology and pharmacology. In: Tober G, Strang J, eds. Methadone matters: evolving community methadone treatment of opiate addiction. London: Martin Dunitz, 2003:45-53.
16. Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. Am Psychol 2004;59:224-35.
17. Hiller ML, Broome KM, Knight K, Simpson DD. Measuring self-efficacy among drug-involved probationers. Psychol Rep 2000;86:529-38.
18. Gossop M, Stewart D, Browne N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002;97:1259-67.
19. Reilly PM, Sees KL, Shopshire MS, et al. Self-efficacy and illicit opioid use in a 180-day methadone detoxification treatment. J Consult Clin Psychol 1995;63:158-62.
20. El Sheikh S, Bashir T. High-risk relapse situations and self-efficacy: comparison between alcoholics and heroin addicts. Addict Behav 2004;29:753-8.
21. Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998;93:1857-67.
22. Saunders JB, Aasland OG, Babor TF, De la Fuente JR, Grant M. Development of the alcohol use disorders inventory test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption (II). Addiction 1993;88:791-804.
23. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated review. J Psychiatr Res 2002;52:69-77.
24. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 2003;1:29. Available at: http://www.hqlo.com/content/1/1/29 (accessed September 2008).
25. Sklar SM,Turner NE. A brief measure for the assessment of coping self-efficacy among alcohol and other drug users. Addiction 1999;94:723-9.
26. Gossop M, Marsden J, Stewart D. The national treatment outcome research study: changes in substance use, health and criminal behaviour during the five years after intake. London: National Addiction Centre, 2001.
27. Dobbler MA, Haettenschwiller J, Meili D, Beck T, Boni E, Modestin J. Patterns of heroin, cocaine and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 2005;29:259-65.
28. Bandura A. Self-efficacy. In: Ramachaudran VS, ed. Encyclopedia of human behaviour. New York: Academic Press, 1994: 71-81. (Reprinted in Friedman H, ed. Encyclopedia of mental health. San Diego, CA: Academic Press, 1998).
29. Carpenter KM. Psychosocial treatments for substance use disorders. Guiding principles for promoting behavioral change. Prim psychiatry 2006;13:43-50.
30. Wanigaratne S, Davis P, Pryce K, Brotchie J. The effectiveness of psychological therapies on drug misusing clients. London: National Treatment Agency, 2005.
31. McKay JR. Co-occurring substance dependence and depression: practical implications and next questions. Addictions 2005;100:1755-7.
32. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004;56:793-802.
33. Turning Point. At the sharp end: 21st century injecting drug use. London, 2007. Available at: http://www.turning-point.co.uk (accessed September 2008).
34. Tennant F, Shannon J. Cocaine abuse in methadone maintenance patients is associated with low serum methadone concentrations. J Addict Dis 1995;14:67-74.
35. Peles E, Kreek MJ, Kellog S, Adelson M. High methadone dose significantly reduces cocaine use in Methadone Maintenance Treatment (MMT) patients. J Addict Dis 2006; 25:43-50.
36. Hartel DM, Schoenbaum EE, Selwyn S, et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health 1995;85:83-8.
37. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry 2002;59:817-24.
38. Lingford-Hughes AR, Welch S, Nutt DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and co-morbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004;18:293-335.